#####
Currently, there are 62.54M common shares owned by the public and among those 55.09M shares have been available to trade.
#####
#####
#####
The company’s stock has a 5-day price change of -4.58% and 17.61% over the past three months. SAGE shares are trading -28.10% year to date (YTD), with the 12-month market performance up to 61.14% higher. It has a 12-month low price of $4.62 and touched a high of $13.47 over the same period. SAGE has an average intraday trading volume of 1.70 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.27%, 10.52%, and 23.55% respectively.
Institutional ownership of Sage Therapeutics Inc (NASDAQ: SAGE) shares accounts for 85.18% of the company’s 62.54M shares outstanding.
It has a market capitalization of $548.00M and a beta (3y monthly) value of 0.26. The earnings-per-share (ttm) stands at -$5.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.00% over the week and 1.24% over the month.
Analysts forecast that Sage Therapeutics Inc (SAGE) will achieve an EPS of -0.94 for the current quarter, -0.86 for the next quarter and -3.16 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.02 while analysts give the company a high EPS estimate of -1.02. Comparatively, EPS for the current quarter was -1.7 a year ago. Earnings per share for the fiscal year are expected to increase by 44.94%, and 20.63% over the next financial year. EPS should grow at an annualized rate of 34.64% over the next five years, compared to 13.20% over the past 5-year period.
#####
Looking at the support for the SAGE, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on March 11, 2025, with the firm’s price target at $5. RBC Capital Mkts coverage for the Sage Therapeutics Inc (SAGE) stock in a research note released on November 21, 2024 offered a Sector Perform rating with a price target of $4. Raymond James was of a view on October 10, 2024 that the stock is Mkt Perform, while RBC Capital Mkts gave the stock Sector Perform rating on October 04, 2024, issuing a price target of $10- $4. TD Cowen on their part issued Hold rating on July 30, 2024.
